Palisade Bio (PALI) Return on Equity (2016 - 2025)
Palisade Bio (PALI) has disclosed Return on Equity for 15 consecutive years, with 3.93% as the latest value for Q3 2025.
- On a quarterly basis, Return on Equity fell 216.0% to 3.93% in Q3 2025 year-over-year; TTM through Sep 2025 was 3.93%, a 216.0% decrease, with the full-year FY2024 number at 1.58%, down 48.0% from a year prior.
- Return on Equity was 3.93% for Q3 2025 at Palisade Bio, down from 3.05% in the prior quarter.
- In the past five years, Return on Equity ranged from a high of 2.57% in Q3 2021 to a low of 3.93% in Q3 2025.
- A 5-year average of 1.23% and a median of 1.38% in 2024 define the central range for Return on Equity.
- Peak YoY movement for Return on Equity: skyrocketed 190bps in 2021, then plummeted -400bps in 2022.
- Palisade Bio's Return on Equity stood at 2.57% in 2021, then tumbled by -149bps to 1.26% in 2022, then rose by 18bps to 1.03% in 2023, then crashed by -105bps to 2.11% in 2024, then plummeted by -86bps to 3.93% in 2025.
- Per Business Quant, the three most recent readings for PALI's Return on Equity are 3.93% (Q3 2025), 3.05% (Q2 2025), and 2.11% (Q1 2025).